George H. Scherr v. Difco Laboratories, Inc.

401 F.2d 443, 159 U.S.P.Q. (BNA) 257, 1968 U.S. App. LEXIS 5380
CourtCourt of Appeals for the Sixth Circuit
DecidedOctober 3, 1968
Docket18004_1
StatusPublished
Cited by7 cases

This text of 401 F.2d 443 (George H. Scherr v. Difco Laboratories, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
George H. Scherr v. Difco Laboratories, Inc., 401 F.2d 443, 159 U.S.P.Q. (BNA) 257, 1968 U.S. App. LEXIS 5380 (6th Cir. 1968).

Opinion

CELEBREZZE, Circuit Judge.

This diversity action was brought to recover royalty payments allegedly due under a patent licensing agreement. Scherr, Plaintiff-Appellee, granted a nonexclusive license under United States Patent 24,557 to Difco Laboratories, Inc., Defendant-Appellant, to make, use, and sell a certain licensed product. When Difco failed to pay the royalties specified in the agreement or to account for sales of the licensed product as provided in the agreement, Scherr brought this action in the United States District Court for the Eastern District of Michigan for specific performance of the licensing agreement, for an accounting and for damages. The District Court granted the relief requested, and Difco has appealed. We vacate the judgment of the District Court and remand the cause for clarification and further findings.

Scherr contends that, under the license agreement, he is entitled to the prescribed royalties even though the patent upon which the license was granted has been held invalid; Difco contends, to the contrary, that the holding of invalidity excused the further payment of royalties. Thus the parties frame the conflict that has brought them to court, basing their antithetic contentions on a license agreement that is silent concerning patent invalidity. 1

The license agreement resulted from the settlement of an infringement action brought by Scherr against Difco. The alleged infringement was the manufacture of a device for testing the sensitivity of microbial organisms to antibiotics and sulfonamides. Both parties manufacture such devices. Scherr’s product is sold under the trademark “Multidisk”; Difco’s device carries the trademark, “Unidisk”. At the same time *445 Scherr sued Difco, he also brought an infringement action against National Bio-Test, Inc., the manufacturer of a sensitivity testing device trademarked “Desi-Disc”. All three devices perform the same function in essentially the same manner; and since Difco was sharing the cost of National Bio-Test’s defense and Scherr was being burdened with the cost of two trials in different districts, a settlement was apparently agreeable to both parties.

The product of the negotiations leading to the settlement was a document labeled “License Agreement” but also containing provisions settling the pending suit. By the terms of that document, Scherr dismissed the suit without prejudice to his “right to reinstate the action for cause”; Difco paid $3,000, “in satisfaction of past infringement”; and Scherr granted Difco a “non-exclusive license under United States Reissue Patent 24,557 to make, use, and sell the license product in the United States.” Immediately following the provision granting the license were provisions establishing the manner in which royalties would be paid. In addition paragraphs 10 and 11 of the document provided for cancellation of the agreement and royalty-free production of certain products as follows:

“10. This agreement may be can-celled by Difco at any time after the first contract year upon six months’ prior notice in writing upon the occurrence of either of the following events:
(1) If Difco completely ceases to manufacture, use, or sell the licensed product:
(2) If, after Difco furnishes Scherr proof of an infringing structure, Scherr fails either to abate the infringement or bring and diligently prosecute a suit against the infringer within six months of receipt of such proof.
“11. Difco shall have the right to make, use, and sell, royalty-free, any product which has been ruled not to infringe the Scherr Reissue Patent 24,-557 by any Court of competent jurisdiction and last resort or from which no timely appeal has been taken by Scherr.”

The agreement was made on July 1, 1959, in Detroit, Michigan, and apparently some royalty payments have been made by Difco. On March 10, 1961, however, the United States District Court for the District of Nebraska held United States Reissue Patent 24,557 “void for want of invention”, Scherr v. National Bio-Test, Inc., 197 F.Supp. 372, 378 (D.Neb.1961). That decision was affirmed by the Eighth Circuit, Scherr v. National Bio-Test, Inc., 301 F.2d 901 (8th Cir. 1962), and no review of that judgment was sought. On'August 1, 1962, in answer to an inquiry from Scherr concerning overdue royalty payments, Difco replied, “It was our understanding * * * that if you were unsuccessful in your suit against National Bio-Test, Inc., and your patent was ruled invalid, that we would be in the clear and under no further obligation to pay you royalties.” Although Difco admits its obligation to pay all royalties accruing before the date of the decision of the Eighth Circuit, it denies any obligation to pay and has refused to pay any royalties accruing after that date.

Difco bases its refusal to pay primarily on the contention that under our decision in Drackett Chemical Co. v. Chamberlain Co., 63 F.2d 853 (6th Cir. 1933), the holding of invalidity by the Eighth Circuit was an eviction justifying termination of the license. In its argument on the defense based upon paragraph 11 of the agreement, Difco, in effect asks this Court to read into the agreement the doctrine of equivalents, which is used in patent litigation. But this is not a suit on the patent; it is a suit on the licensing contract, and the District Court properly disposed of the contract issue raised under paragraph 11. The Court, however, misconstrued our opinion in Drackett and as a result failed to make certain findings necessary to a final disposition of this case.

*446 The District Court interpreted Drackett as applying only to exclusive licenses and indicated that the doctrine of eviction would not apply unless specific language in the license agreement provided for royalty-free rights after a final ruling of invalidity. 2 First, the Drackett case involved both an exclusive and a non-exclusive license, 3 and in its disposition of the case the Court squarely held that the holding of eviction applied equally to both:

“It is suggested that • here the license contract was more than a mere license, in that it contained a provision that the Chamberlain Company would not advertise or solicit business from the grocery trade; and that the Drac-kett Chemical Company, having purchased immunity from suits for past or future infringement, by its agreement to pay royalties, should not now be permitted to deny such liability. The first of these suggestions is without weight. Licenses may be exclusive, partially exclusive, or nonexclusive. The principles which we have stated apply with equal force to all these types, * * 63 F.2d at 854-855.

Secondly, application of the doctrine of eviction presumes the absense of any specific language in the agreement.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
401 F.2d 443, 159 U.S.P.Q. (BNA) 257, 1968 U.S. App. LEXIS 5380, Counsel Stack Legal Research, https://law.counselstack.com/opinion/george-h-scherr-v-difco-laboratories-inc-ca6-1968.